Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports
$16,500.00   |  '

Inflammatory Myositis – Executive Insights – Inflammatory Myositis: Executive Insights | US/EU5 | 2022

Login to access report north_east
Buy report north_east

Inflammatory myositis (IM) is a heterogeneous group of autoimmune disorders characterized by immune-mediated muscle injury that results in muscle inflammation and skeletal muscle weakness. Corticosteroids, steroid-sparing agents, and other immunosuppressive drugs are the mainstay for the management of IM. In 2021, Octagam 10% (IVIg) was approved for the treatment of dermatomyositis in the United States and Europe. Targeted assets with novel mechanisms of action (MAb, JAK inhibitor, CTLA-4 agonist, CB2 agonist) are in late-phase development for the treatment of IM. Major unmet needs, including limited approved therapies for IM, present a lucrative commercial opportunity and could drive the future market dynamics.

Questions answered

  • What is the diagnosed prevalence of IM?
  • What is the current market landscape including the diagnostic and management practices across different markets under study?
  • What is the potential impact of pipeline therapies, and how will these therapies affect future IM market dynamics?
  • What are the key unmet needs and areas of opportunity in the management of IM?
  • What are the key drivers and limiters of the IM market?

Product description

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Geography: United States, EU5

Primary research: 13 KOL interviews from November 2021 to January 2022

Key companies covered: Octapharma, BMS, CSL Behring, Corbus Pharmaceuticals, Alexion, Pfizer, Kezar Life Sciences, others

Key drugs covered: Octagam, Orencia, Hizentra, lenabasum, Ultomiris, PF-06823859, KZR-616, others

Table of contents

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
north_east
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east